RITC2026 Information Day

October 28, 2025

Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026)

© gpointstudio – stock.adobe.com

The RITC2026 aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity.

EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches providing more efficient and personalised management of multimorbid patients, having at least two chronic diseases that require management.

Projects will address one or more of the following aspects:

  • Detection or characterisation of co-morbidities in chronically ill patients;
  • Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses;
  • Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions;
  • Decision support for disease intervention strategies (e.g., medication type and dosage);
  • Tracking and managing multiple treatments (including drug combinations) to improve effectiveness or reduce adverse effects and potential harmful drug interactions;
  • Adherence to long-term treatment regimens.

Funded projects are required to test and further develop mature solutions in controlled real-world environments. They should also adopt a holistic system approach by integrating six enabling elements (knowledge integration; technologies, products, methods and processes; infrastructures; business and value models; policies and regulations; organisation; behaviour and values). Furthermore, proposals must clearly describe a robust strategy for the collection, processing, and usage of multimodal health data.

The transnational consortia have mandatorily to include a clinical partner as well as at least one SME (small and medium sized enterprise) or industry partner.

While clinical studies can be funded in this call, larger clinical trials are out of scope.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase. The available budget for this call is 13 Mio. € (approx.).

An information day introducing the RITC2026 to the research community will be organised on 28 October 2025.